World's Best Scientists 2026 revealed!
Martin J.B. Taphoorn

Martin J.B. Taphoorn

Martin J.B. Taphoorn publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Martin J.B. Taphoorn sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

Martin J.B. Taphoorn D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Martin J.B. Taphoorn sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

Martin J.B. Taphoorn is affiliated with Leiden University in the Netherlands. Their research focus lies predominantly within the field of medicine, with significant contributions in genetics, pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, pediatrics, perinatology and child health, as well as psychiatry and mental health.

Their main research topics include glioma diagnosis and treatment, pharmacological effects and toxicity studies, epilepsy research and treatment, cancer-related cognitive impairment studies, brain metastases and treatment, cancer survivorship and care, and meningioma and schwannoma management.

Taphoorn has contributed to several frequently cited papers, notably:

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood, 2020, Nature Reviews Clinical Oncology
  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions, 2020, Neuro-Oncology
  • Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up, 2020, Annals of Oncology
  • International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium, 2020, The Lancet Oncology
  • Transcriptome analysis reveals tumor microenvironment changes in glioblastoma, 2023, Cancer Cell

Taphoorn has collaborated frequently with several researchers, including Linda Dirven, Johan A F Koekkoek, Martin J. van den Bent, Jaap C. Reijneveld, and Pim B. van der Meer.

Their work appears consistently in prominent publication venues such as Neuro-Oncology, Neuro-Oncology Practice, Journal of Neuro-Oncology, Neuro-Oncology Advances, and the European Journal of Cancer.

Best Publications

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

    Roger Stupp;Warren P. Mason;Martin J. van den Bent;Michael Weller

  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

    Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent

  • Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

    Martin J. van den Bent;Alba A. Brandes;Martin J.B. Taphoorn;Johan M. Kros

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

    Michael Weller;Martin van den Bent;Matthias Preusser;Emilie Le Rhun

  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

    Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge

  • Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

    Martin J. van den Bent;Antoine F. Carpentier;Alba A. Brandes;Marc Sanson

  • European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

    Michael Weller;Martin van den Bent;Jörg C Tonn;Roger Stupp

  • Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

    Walter Taal;Hendrika M Oosterkamp;Annemiek M E Walenkamp;Hendrikus J Dubbink

  • Lomustine and Bevacizumab in Progressive Glioblastoma

    Wolfgang Wick;Thierry Gorlia;Martin Bendszus;Martin Taphoorn

  • Cognitive deficits in adult patients with brain tumours.

    Martin J.B. Taphoorn;Martin Klein

  • Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up

    Linda Douw;Martin Klein;Selene S. A. A. Fagel;Josje van den Heuvel

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Patrick Y. Wen;Michael Weller;Eudocia Quant Lee;Brian M. Alexander

  • Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

    Martin J. van den Bent;Alba A. Brandes;Roy Rampling;Mathilde C.M. Kouwenhoven

  • Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

    M. J. van den Bent;J. S. Wefel;D. Schiff;M. J. B. Taphoorn

  • Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life.

    Martin Klein;Nadine H J Engelberts;Henk M van der Ploeg;Dorotheé G A Kasteleijn-Nolst Trenité

  • Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

    Brigitta G Baumert;Brigitta G Baumert;Monika E Hegi;Martin J van den Bent;Andreas von Deimling

  • High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non–AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962

    Philip M.P. Poortmans;Hanneke C. Kluin-Nelemans;Hanny Haaxma-Reiche;Mars Van’t Veer

  • Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971

    M J van den Bent;M J B Taphoorn;A A Brandes;Johan Menten

  • Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology

    Khê Hoang-Xuan;Eric Bessell;Jacoline Bromberg;Andreas F Hottinger

  • IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

    Martin J. van den Bent;Hendrikus J. Dubbink;Yannick Marie;Alba A. Brandes

Frequent Co-Authors

Martin Klein
Martin Klein Vrije Universiteit Amsterdam
Andrew Bottomley
Andrew Bottomley European Organisation for Research and Treatment of Cancer
Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
Roger Stupp
Roger Stupp Northwestern University
Neil K. Aaronson
Neil K. Aaronson Antoni van Leeuwenhoek Hospital
Wolfgang Wick
Wolfgang Wick German Cancer Research Center
Luc Deliens
Luc Deliens Vrije Universiteit Brussel
Alba A. Brandes
Alba A. Brandes Institute of Neurological Sciences
Michael Weller
Michael Weller University of Zurich
Madeleine King
Madeleine King University of Sydney

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a wide variety of online degrees and fast-tracked career options. Many students seek flexible and accelerated programs to fit their schedules and personal goals.

For those interested in advanced nursing, the easiest dnp program reddit forums and guides can help identify Doctor of Nursing Practice paths that are both accessible and reputable. If you're considering beginning your nursing journey, look into fast track lpn programs, which offer streamlined routes to licensure.

Mental health is also a growing field with high demand. Careers such as psychiatric nurse practitioners are increasingly accessible through psych nurse practitioner programs online, providing both speed and flexibility.

Not all healthcare careers focus on patient care. If you’re inclined toward administration, consider the healthcare administration degrees offered online, allowing you to manage systems and improve care delivery without clinical requirements.

Best Scientists Citing Martin J.B. Taphoorn

Trending Scientists